179 related articles for article (PubMed ID: 25284284)
21. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.
Dueregger A; Heidegger I; Ofer P; Perktold B; Ramoner R; Klocker H; Eder IE
Nutrients; 2014 Oct; 6(10):4491-519. PubMed ID: 25338271
[TBL] [Abstract][Full Text] [Related]
22. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer.
Song C; Park S; Park J; Shim M; Kim A; Jeong IG; Hong JH; Kim CS; Ahn H
Prostate; 2015 Feb; 75(2):211-7. PubMed ID: 25327522
[TBL] [Abstract][Full Text] [Related]
23. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.
Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Polkinghorn W; McBride S; Kollmeier M; Yamada Y; Zelefsky MJ
Eur Urol; 2015 Jun; 67(6):1009-1016. PubMed ID: 25308970
[TBL] [Abstract][Full Text] [Related]
24. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
25. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
26. Clinical predictors and recommendations for staging computed tomography scan among men with prostate cancer.
Risko R; Merdan S; Womble PR; Barnett C; Ye Z; Linsell SM; Montie JE; Miller DC; Denton BT
Urology; 2014 Dec; 84(6):1329-34. PubMed ID: 25288575
[TBL] [Abstract][Full Text] [Related]
27. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.
Kim W; Zhang L; Wilton JH; Fetterly G; Mohler JL; Weinberg V; Morse A; Szmulewitz RZ; Friedlander TW; Fong L; Lin AM; Harzstark AL; Molina A; Small EJ; Ryan CJ
Clin Cancer Res; 2014 Dec; 20(24):6269-76. PubMed ID: 25336698
[TBL] [Abstract][Full Text] [Related]
28. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
[TBL] [Abstract][Full Text] [Related]
29. Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.
Mathieu R; Shariat SF; Seitz C; Karakiewicz PI; Fajkovic H; Sun M; Lotan Y; Scherr DS; Tewari A; Montorsi F; Briganti A; Rouprêt M; Lucca I; Margulis V; Rink M; Kluth LA; Rieken M; Bachman A; Xylinas E; Robinson BD; Bensalah K; Margreiter M
World J Urol; 2015 Aug; 33(8):1165-71. PubMed ID: 25344896
[TBL] [Abstract][Full Text] [Related]
30. Biologic differences between peripheral and transition zone prostate cancer.
Lee JJ; Thomas IC; Nolley R; Ferrari M; Brooks JD; Leppert JT
Prostate; 2015 Feb; 75(2):183-90. PubMed ID: 25327466
[TBL] [Abstract][Full Text] [Related]
31. Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.
Spratt DE; Zumsteg ZS; Pei X; Romesser PB; Yamada J; Kollmeier MA; Woo K; Zhang Z; Zelefsky MJ
Prostate; 2015 Feb; 75(2):175-82. PubMed ID: 25327412
[TBL] [Abstract][Full Text] [Related]
32. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy.
Seisen T; Rouprêt M; Brault D; Léon P; Cancel-Tassin G; Compérat E; Renard-Penna R; Mozer P; Guechot J; Cussenot O
Prostate; 2015 Jan; 75(1):103-11. PubMed ID: 25327361
[TBL] [Abstract][Full Text] [Related]
33. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics.
Xia J; Trock BJ; Gulati R; Mallinger L; Cooperberg MR; Carroll PR; Carter HB; Etzioni R
Clin Cancer Res; 2014 Oct; 20(20):5302-10. PubMed ID: 25320374
[TBL] [Abstract][Full Text] [Related]
34. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
[TBL] [Abstract][Full Text] [Related]
35. Is there any prognostic impact of intraductal carcinoma of prostate in initial diagnosed aggressively metastatic prostate cancer?
Zhao T; Liao B; Yao J; Liu J; Huang R; Shen P; Peng Z; Gui H; Chen X; Zhang P; Zhu Y; Li X; Wei Q; Zhou Q; Zeng H; Chen N
Prostate; 2015 Feb; 75(3):225-32. PubMed ID: 25307858
[TBL] [Abstract][Full Text] [Related]
36. Establishment of a new prostate cancer multidisciplinary clinic: Format and initial experience.
Sundi D; Cohen JE; Cole AP; Neuman BP; Cooper J; Faisal FA; Ross AE; Schaeffer EM
Prostate; 2015 Feb; 75(2):191-9. PubMed ID: 25307625
[TBL] [Abstract][Full Text] [Related]
37. Capsaicin: a novel radio-sensitizing agent for prostate cancer.
Venier NA; Colquhoun AJ; Sasaki H; Kiss A; Sugar L; Adomat H; Fleshner NE; Klotz LH; Venkateswaran V
Prostate; 2015 Feb; 75(2):113-25. PubMed ID: 25307418
[TBL] [Abstract][Full Text] [Related]
38. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
Doctor SM; Tsao CK; Godbold JH; Galsky MD; Oh WK
Cancer; 2014 Mar; 120(6):833-9. PubMed ID: 25302607
[TBL] [Abstract][Full Text] [Related]
39. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
40. The association between selenium and other micronutrients and thyroid cancer incidence in the NIH-AARP Diet and Health Study.
O'Grady TJ; Kitahara CM; DiRienzo AG; Gates MA
PLoS One; 2014; 9(10):e110886. PubMed ID: 25329812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
